参考文献/References:
[1]Cuker A,Neunert CE.How I treat refractory immune thrombocytopenia[J].Blood,2016,28(12):1547-1554.
[2]郭珊珊,于天启,陈志雄,等.原发免疫性血小板减少症(下篇)[J].血栓与止血学,2016,2(2):195-199.
[3]中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(2):89-93.
[4]侯明,秦平.成人原发免疫性血板减少症诊治的中国专家共识(2016版)解读[J].临床血液学杂志,2016,29(7):523-527.
[5]Provan D,Stasi R,Newland AC,et al.International consensus report on the investigation and management of primaryimmune thrombocytopenia[J].Blood,2010,115(2):168-186.
[6]Pace DE,Chiasson PM,Schlachta CM,et al.Laparoscopic splenectomy for idiopathic thrombocytopenic purpura(ITP)[J].Surg Endosc,2003,17(1):95-98.
[7]Houwerzijl EJ,Blom NR,vander Want JJL,et al.Ultrastructural study shows morph ological features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura[J].Blood,2004,103(2):500-506.
[8]Neunert CE.Current management of immune thrombocytopenia[J].Hematology Am Soc Hematol Educ Program,2013,2013(4):276-282.
[9]Kuter DJ.Romiplostim[J].Cancer Treatment&Research,2011,157(157):267-288.
[10]Kuter DJ,Bussel JB.Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia:safety an efficacy[J].Br J Haematol,2013,161(3):411-423.
[11]Imbach P,Crowther M.Thrombopoietin-receptor agonists for primary immune thrombocytopenia[J].N Engl J Med,2011,365(8):734-741.
[12]Tarantino MD,Bussel JB,Blanchette VS,et al.Romiplostim in children with immune thrombocytopenia:a phase 3,randomised,double-blind,placebo-controlled study[J].Lancet,2016,388(10039):45-54.
[13]Yang R,Li J,Jin J,et al.Multicentre,randomised phase Ⅲ study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia[J].Br J Haematol,2017,176(1):101-110.
[14]Kim YK,Lee SS,Jeong SH,et al.Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia[J].Blood Res,2015,50(1):19-25.
[15]Burzynski J.New options after first-line therapy for chronic immune thrombocytopenic purpura[J].American Journal ofHealth-System Pharmacy,2009,66(2):11-21.
[16]Jun Seok Yoon,Yoo Jin Lee,Dong Won Baek,et al.New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients[J].Korean J Intern Med,2016,36(8):252-254.
[17]Miyakawa Y,Katsutani S,Yano T,et al.Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy[J].International Journal of Hematology,2015,102(6):654-661.
[18]Hammond WA,Rodriguez EM,Li Z,et al.Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia(ITP):The Mayo Clinic Experience[J].Blood,2016(128):3735.
[19]Song I,Kim J,Kwon K,et al.Expression of CD154(CD40L) on stimulated T lymphocytes in patients with idopathic thrombocytopenic purpura[J].Hematology,2016,3(21):187-192.
[20]Patel VL,Schwartz J,Bussel JB.The effect of anti-CD40 ligand in immune thrombocytopenic purpura[J].Br J Haematol,2010,141(4):545-548.
[21]Liebman HA,Saleh MN,Bussel JB,et al.Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia[J].Hematology,2016,101(11):1327-1332.
[22]Robak T,Windyga J,Thhnski J,et al.Rozmlimupab,a mixture of 25 recombinant human monoclonal RhD antibodies,in the treatment of primary immune thrombocytopenia[J].Blood,2012,120(18):3670-3676.
[23]Konstaninova TS,Leonidovna IV,Hellmann A,et al.Interim results from a PhaseⅠbⅡa clinical trial with the soluble Fc-gamma Ⅱb receptor SM101 for the treatment of primary immune thrombocytopenia[J].Polski Tygodnik Lekarski,2012,23(25):950-953.
[24]Podolanczuk A,Lazarus AH,Crow AR,et al.Of mice and men:an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk[J].Blood,2009,113(14):3154-3160.
[25]Bussel JB,Kuter DJ,Aledort LM,et al.A randomized trial of avatrombopag,an investigational thrombopoietin-receptor agonist,in persistent and chronic immune thrombocytopenia[J].Blood,2014,123(25):3887-3894.
[26]Poudyal BS,Sapkota B,Shrestha GS,et al.Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura[J].Journal of Nepal Medical Association,2016,55(203):16-21.
[27]Choi PY,Roncolato F,Badoux X,et al.A novel triple therapy for ITP using high-dose dexamethasone,low-dose rituximab, and cyclosporine(TT4)[J].Blood,2015,126(4):500-503.
[28]Faiz Anwer,Seongseok Yun,Anju Nair,et al.Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag[J].Case Reports in Hematology,2015(9):583451.
[29]Stirnemann J,Kaddouri N,Khellaf M,et al.Vincristine efficacy and safety in treating immune thrombocytopenia:a retrospective study of 35 patients[J].European Journal of Haematology,2016,96(3):269-275.
[30]Gasbarrini A,Franceschi F,Tartaglione R,et al.Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori[J].Lancet,1998,352(9131):878.
[31]Takahashi T,Yujiri T,Shinohara K,et al.Molecular mimicry by Heli-cobacter pylori CagA protein may be involved in the patho-genesis of H.pylori-associated chronic idiopathic throm-bocytopenic purpura[J].Br J Haematol,2004,124(1):91-96.
[32]Veneri D,Matteis GD,Solero P,et al.Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura:correlation with Helicobacter pylori infection and response to eradication treatment[J].Platelets,2005,16(5):307-311.
[33]Asahi A,Kuwana M,Suzuki H,et al.Therapeutic action of Helicobacter pylori eradication patients with chronic ITP-Lessons from eradication therapy on H.pylori-negative patients[J].Blood,2004,92(2):563-570.
[34]Semple JW,Aslam R,Kim M,et al.Platelet-bound lipopolysaccharide enhances Fc receptor mediated phagocytosis of IgG-opsonized platelets[J].Blood,2007,109(11):4803-4805.
[35]张励,马茉娇,刘小宇,等.幽门螺旋杆菌感染与Hp的相关性研究[J].临床军医杂志,2011,39(6):1272-1273.
[36]Takafuta T,Fujimura K.Helicobacter pylori(H.pylori)Eradication[J].Autoimmune Thrombocytopenia,2017:135-143.
[37]Fujimura K,Kuwana M,Kurata Y,et al.Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura.Analysis of 207 eradicated chronic ITP cases in Japan[J].Int J Hematol,2005,81(2):162-168.
[38]Hwang JJ,Lee DH,Yoon H,et al.The Effects of Helicobacter pylori Eradication Therapy for Chronic Idiopathic Thrombocytopenic Purpura[J].Gut Liver,2016,10(3):356-361.
相似文献/References:
[1]钟时嘉.亚急性甲状腺炎的临床分析[J].医学信息,2018,31(01):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
ZHONG Shi-jia.Clinical Analysis of Subacute Thyroiditis[J].Journal of Medical Information,2018,31(05):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
[2]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Journal of Medical Information,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[3]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Journal of Medical Information,2018,31(05):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[4]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(05):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[5]刘广涛,关凤军,董 晨.原发性肾病综合征患儿肾组织P-gp170蛋白和mRNA表达与临床病理及预后的关系[J].医学信息,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
LIU Guang-tao,GUAN Feng-jun,DONG Chen.Relationship between the Expression of p-gp170 Protein and mRNA in Renal Tissue of Children with Primary Nephrotic Syndrome and Clinical Pathology and Prognosis[J].Journal of Medical Information,2018,31(05):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
[6]陈晓霞,唐 勇,胡 庆,等.吗替麦考酚酯联合糖皮质激素治疗特发性膜性肾病的疗效观察[J].医学信息,2018,31(22):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
CHEN Xiao-xia,TANG Yong,HU Qing,et al.Therapeutic Effect of Mycophenolate Mofetil Combined with Glucocorticoid on Idiopathic Membranous Nephropathy[J].Journal of Medical Information,2018,31(05):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
[7]高 鹏,高 浩,燕 飞.坏疽性脓皮病1例[J].医学信息,2019,32(01):191.[doi:10.3969/j.issn.1006-1959.2019.01.063]
[8]马艳艳,刘建军.肌无力危象的治疗研究进展[J].医学信息,2019,32(06):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
MA Yan-yan,LIU Jian-jun.Progress in the Treatment of Myasthenia Crisis[J].Journal of Medical Information,2019,32(05):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
[9]谢卫强,巩 栋,高明暄,等.关节病性银屑病伴髋关节结核1例[J].医学信息,2019,32(07):189.[doi:10.3969/j.issn.1006-1959.2019.07.062]
[10]王立英.糖皮质激素治疗突发性聋的研究[J].医学信息,2019,32(11):52.[doi:10.3969/j.issn.1006-1959.2019.11.015]
WANG Li-ying.Glucocorticoid Therapy for Sudden Deafness[J].Journal of Medical Information,2019,32(05):52.[doi:10.3969/j.issn.1006-1959.2019.11.015]